Bispecific antibodies in the treatment of multiple myeloma

FDA Approval of Bispecific Antibodies for Multiple Myeloma a ...

Bispecific antibodies represent a “meaningful step” in multiple myeloma treatment, experts say. These agents, also known as T-cell engagers ...

Paper: Efficacy of Bispecific Antibodies Vs CAR-T in the Treatment of ...

Bispecific antibodies (BsAb) and Chimeric antigen receptor T-cell therapy (CAR-T) have emerged as a promising treatment option for patients with relapsed, ...

BCMA-Targeted Bispecific Antibodies Are 'Encouraging' for Some ...

There are currently 3 FDA-approved bispecific antibodies in the relapsed/refractory multiple myeloma space: teclistamab (Tecvayli), elranatamab ...

Treatment of Relapsed Multiple Myeloma With Bispecific Antibodies

We spent time discussing current treatment options, including both chimeric antigen receptor (CAR) T-cell therapy and the bispecific antibody (BsAb) ...

Bispecific Antibodies Advance the Treatment of Multiple Myeloma

Linvoseltamab (REGN5458) and REGN5459 are BCMA x CD3 bispecific antibodies designed to bind to the BCMA present on multiple myeloma cells and ...

Treatment of Relapsed or Refractory Multiple Myeloma With BCMA ...

In contrast, bispecific antibodies, while sharing some side effects with CAR T-cells, generally exhibit milder and more preventable adverse reactions, often ...

Characteristics and incidence of infections in patients with multiple ...

Bispecific antibodies (BsAbs) are an effective treatment used in relapsed or refractory multiple myeloma. Despite a well-tolerated safety profile, ...

Bispecific antibody treatment of multiple myeloma: latest updates ...

This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the ...

Bispecific Antibodies for the Treatment of Multiple Myeloma

We review the preclinical and clinical development of bispecific antibodies for MM and discuss their potential roles in the treatment of multiple myeloma.

Managing Bispecific Antibody–Associated AEs in Myeloma | myCME

Recent advances in multiple myeloma treatment include a variety of new and novel treatments. Of these, bispecific antibody therapy, a powerful form of ...

Bispecific Antibodies and the Dawn of a New Era in Treatment of ...

Relapsed and refractory multiple myeloma remains a treatment challenge. Promising responses have been demonstrated with bispecific antibodies, ...

Analysis Shows Further Evidence for Fixed-Duration Bispecific ...

The median duration of bispecific antibody treatment was 7.6 months (range, 1-52 months). Infection was the most common reason for treatment ...

The role of bispecific antibodies in the treatment of ... - YouTube

... bispecific antibodies in the treatment of multiple myeloma (MM). In the past few years, three bispecifics have been approved for MM. They ...

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

Treatment with bispecific antibodies (bsAbs) is an immunotherapeutic strategy that leads to an enhanced interaction between MM cells and immune effector cells, ...

CAR-T Versus Bispecific Antibodies in Multiple Myeloma

CAR T-Cell Therapy: Best Option for Patients · Bispecifics Will Overtake CAR T Cells in Myeloma Treatment · Related Posts.

Factors to consider when selecting patients with multiple myeloma ...

when considering bispecific antibody treatment for patients with multiple myeloma, including age and the pace at which the disease is

Optimizing Bispecific Antibody Therapy in Multiple Myeloma

This resource guide is a review of bispecific antibodies, one of the new therapies currently being studied in clinical trials for patients with RRMM.

Bispecific Antibodies for the Treatment of ... - Multiple Myeloma

The data confirm the feasibility and safety of this dual BsAb combination designed to target distinct myeloma antigens. They also support the ...

Bispecific Antibody Combos for R/R Myeloma: What to Know

Tara Gregory, MD, explains what bispecific antibody combinations have been approved for relapsed/refractory multiple myeloma, potential side ...

Current status of bispecific antibodies and CAR-T therapies in ...

Clinical trials of bispecific antibodies against multiple myeloma ... Bispecific antibodies are engineered molecules designed to simultaneously ...